{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:53:06Z","timestamp":1792007586981,"version":"4.4.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n                           <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT is indicated for selecting patients for peptide receptor radionuclide therapy (PRRT). Although highly sensitive, the detectability of smaller lesions, particularly in the liver, is lower. We present the case of a 58-year-old man with metastatic well-differentiated pancreatic neuroendocrine tumor whose MRI revealed progression of hepatic metastases. <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT performed to determine eligibility for PRRT did not demonstrate DOTATATE-avid disease within the liver. <jats:sup>18<\/jats:sup>F-FDG PET\/CT was also negative at the liver and the patient proceeded to <jats:sup>177<\/jats:sup>Lu-DOTATATE PRRT, where multi\u2013time point posttherapy planar imaging and SPECT\/CT showed intense uptake in the known liver metastases.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004434","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T23:08:19Z","timestamp":1665788899000},"page":"e12-e15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET\/CT and 177Lu-DOTATATE SPECT\/CT"],"prefix":"10.1097","volume":"48","author":[{"given":"Hanan","family":"Zahed","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Jewish General Hospital, McGill University, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Mathieu","family":"Beauregard","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, CHU de Qu\u00e9bec\u2013Universit\u00e9 Laval; and Department of Radiology and Nuclear Medicine, Universit\u00e9 Laval, Quebec City, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Abikhzer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jewish General Hospital, McGill University, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rush","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jewish General Hospital, McGill University, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Probst","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jewish General Hospital, McGill University, Montreal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","year":"2015","journal-title":"Radiographics"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current concepts in 68Ga-DOTATATE imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I\u2013II study","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000348394","article-title":"Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors","volume":"97","year":"2013","journal-title":"Neuroendocrinology"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib8-20250621","first-page":"27","article-title":"Physical characteristics of 68Ga DOTATATE PET\/CT affecting small lesion detectability","volume":"11","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13550-021-00839-x","article-title":"Automated liver lesion detection in 68Ga DOTATATE PET\/CT using a deep fully convolutional neural network","volume":"11","year":"2021","journal-title":"EJNMMI Res"},{"key":"bib10-20250621","first-page":"395","article-title":"Integrating early rapid post-peptide receptor radionuclide therapy quality assurance scan into the outpatient setting","volume":"10","year":"2019","journal-title":"J Nucl Med Radiat Ther"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-011-2003-x","article-title":"Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET\/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy","volume":"39","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:02:29Z","timestamp":1750536149000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004434","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}